Business
Press Release May 12 2026
Suven Life Sciences Limited has informed the Exchange regarding a press release dated May 12, 2026, titled "Suven Life Sciences Reaches 76% Enrollment milestone in Global Phase 3 Masupirdine (SUVN-502) Trial for Agitation in Alzheimer s Dementia".
About this update from Suven Life Sciences Limited
[{"type":"text","content":" Suven Life Sciences Limited has informed the Exchange regarding a press release dated May 12, 2026, titled \"Suven Life Sciences Reaches 76% Enrollment milestone in Global Phase 3 Masupirdine (SUVN-502) Trial for Agitation in Alzheimer s Dementia\". View Attachment","length":405,"tagName":"div"}]